Targeting protein-bound uremic toxins in chronic kidney disease

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 11, 2013, Pages 1287-1301

  Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Indoxyl sulfate; Oral adsorbent AST 120

Indexed keywords

AST 120; INDICAN; INDOLE; ORGANIC ANION TRANSPORTER; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; UREMIC TOXIN;

BONE DISEASE; CARDIOVASCULAR DISEASE; CELLS; CHRONIC KIDNEY DISEASE; DIET; DISEASE COURSE; ENDOTHELIUM CELL; FIBROBLAST; GLOMERULAR MESANGIAL CELL; HEMODIALYSIS; HUMAN; INTESTINE; INTESTINE FLORA; KIDNEY; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MESANGIUM CELL; METABOLISM; MODULATION; MONOCYTE; MUSCLE CELL; NEPHROTOXICITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SENESCENCE; UREMIA; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

BONE AND BONES; CARBON; CARDIOVASCULAR SYSTEM; DISEASE PROGRESSION; ERYTHROPOIETIN; HUMANS; INDICAN; KIDNEY; KIDNEY FAILURE, CHRONIC; OXIDES; PROTEIN BINDING; REACTIVE OXYGEN SPECIES;

EID: 84886923823     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.829456     Document Type: Review

References (129)

1. Niwa T. Uremic toxins. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2012
2. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43
3. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012;23:1258-70
4. Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1662-8
5. Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2997-3002
6. Akiyama Y, Takeuchi Y, Kikuchi K, et al. A metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). Toxins 2012;4:1309-22
7. Itoh Y, Ezawa A, Kikuchi K, et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 2012;403:1841-50
8. Sirich TL, Aronov PA, Plummer NS, et al. Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 2013; [Epub ahead of print]
9. Aronov PA, Luo FJ, Plummer NS, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011;22:1769-76
10. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104
11. Niwa T, Yazawa T, Ise M, et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron 1991;57:84-8
12. Niwa T, Emoto Y, Maeda K, et al. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant 1991;6:105-9
13. Niwa T, Miyazaki T, Hashimoto N, et al. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992;12:201-6
14. Niwa T, Miyazaki T, Tsukushi S, et al. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996;74:72-8
15. Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: effects of low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab 1997;23:179-84
16. Niwa T, Nomura T, Sugiyama S, et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997;52(Suppl 62):S23-8
17. Miyazaki T, Aoyama I, Ise M, et al. An oral sorbent reduces overload of indoxyl sulfate and gene expression of TGF-beta1 in uremic rat kidneys. Nephrol Dial Transplant 2000;15:1773-81
18. Niwa T. Uremic toxicity. Indoxyl sulfate. In: Massry SG, Glassock RJ, editors. Textbook of nephrology. Lippincott Williams & Wilkins; Philadelphia: 2001. p. 1269-72
19. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994;14:207-12
20. Miyazaki T, Ise M, Seo H, et al. Indoxyl sulfate increases the gene expressions of TGF-beta1, TIMP-1 and proalpha1(I) collagen in kidneys of uremic rats. Kidney Int 1997;52(Suppl 62):S15-22
21. Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta1 and progression of renal failure. Kidney Int 1997;52(Suppl 63):S211-14
22. Niwa T. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 1996;16:167-82
23. Niwa T, Aoyama I, Takayama F, et al. Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner Electrolyte Metab 1999;25:118-22
24. Aoyama I, Miyazaki T, Takayama F, et al. Oral adsorbent ameliorates renal TGF-beta1 expression in hypercholesterolemic rats. Kidney Int 1999;56(Suppl 71):S193-7
25. Aoyama I, Miyazaki T, Niwa T. Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab 1999;25:365-72
26. Aoyama I, Shimokata K, Niwa T. Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta1 expression in spontaneously diabetic (OLETF) rats. Am J Nephrol 2000;20:232-41
27. Aoyama I, Niwa T. Molecular insights into preventive effect of AST-120 on the progression of renal failure. Clin Exp Nephrol 2001;5:209-16
28. Aoyama I, Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis 2001;37(Suppl 2):S7-12
29. Aoyama I, Shimokata K, Niwa T. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron 2002;90:297-312
30. Aoyama I, Shimokata K, Niwa T. An oral adsorbent down-regulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron 2002;92:635-51
31. Aoyama I, Enomoto A, Niwa T. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. Am J Kidney Dis 2003;41(Suppl 1):S8-14
32. Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003;63:1671-80
33. Gelasco AK, Raymond JR. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006;290:F1551-8
34. Owada S, Goto S, Bannai K, et al. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008;28:446-54
35. Taki K, Niwa T. Indoxyl sulfate-lowering capacity of oral sorbents affects prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr 2007;17:48-52
36. Tumur Z, Niwa T. An oral sorbent AST-120 increases renal NO synthesis in uremic rats. J Ren Nutr 2008;18:60-4
37. Trachtman H. Nitric oxide and glomerulonephritis. Semin Nephrol 2004;24:324-32
38. Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002;13:1711-20
39. Enomoto A, Takeda M, Taki K, et al. Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol 2003;466:13-20
40. Taki K, Nakamura S, Miglinas M, et al. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006;16:199-203
41. Deguchi T, Takemoto M, Uehara N, et al. Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J Pharmacol Exp Ther 2005;314:932-8
42. Shimizu H, Bolati D, Higashiyama Y, et al. Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-kappaB, p53, ERK, and JNK in proximal tubular cells. Life Sci 2012;90:525-30
43. Shimizu H, Yisireyili M, Higashiyama Y, et al. Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-kappaB and p53 in proximal tubular cells. Life Sci 2013;92:143-8
44. Bolati D, Shimizu H, Higashiyama Y, et al. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol 2011;34:318-23
45. Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-to- mesenchymal transition and interstitial fibrosis in the kidneys of CKD rats. J Ren Nutr 2012;22:176-80
46. Shimizu H, Yisireyili M, Nishijima F, Niwa T. Stat3 contributes to indoxyl sulfate-induced inflammatory and fibrotic gene expression and cellular senescence. Am J Nephrol 2012;36:184-9
47. Shimizu H, Yisireyili M, Nishijima F, et al. Indoxyl sulfate enhances p53-TGF-beta1-Smad3 pathway in proximal tubular cells. Am J Nephrol 2013;37:97-103
48. Kim SH, Yu MA, Ryu ES, et al. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest 2012;92:488-98
49. Bolati D, Shimizu H, Yisireyili M, et al. Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-kappaB. BMC Nephrol 2013;14:56
50. Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 2013;28:70-8
51. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 1997;390:45-51
52. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of Klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-20
53. Adijiang A, Shimizu H, Higuchi Y, et al. Indoxyl sulfate reduces Klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr 2011;21:105-9
54. Adijiang A, Niwa T. An oral sorbent AST-120 increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 2010;31:160-4
55. Shimizu H, Bolati D, Adijiang A, et al. Indoxyl sulfate downregulates renal expression of Klotho through production of ROS and activation of NF-kappaB. Am J Nephrol 2011;33:319-24
56. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012;81:640-50
57. Shimizu H, Bolati D, Adijiang A, et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol Cell Physiol 2010;299:C1110-17
58. Shimizu H, Bolati D, Adijiang A, et al. NF-kappaB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression and inhibition of proliferation in proximal tubular cells. Am J Physiol Cell Physiol 2011;301:C1201-12
59. Shimizu H, Saito S, Higashiyama Y, et al. CREB, NF-kappaB, and NADPH oxidase coordinately upregulate indoxyl sulfate-induced angiotensinogen expression in proximal tubular cells. Am J Physiol Cell Physiol 2013;304:C685-92
60. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 2012;7:e34026
61. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-51
62. Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006;69:1780-5
63. Muteliefu G, Enomoto A, Niwa T. Indoxyl sulfate promotes proliferation of human aortic smooth muscle cells by inducing oxidative stress. J Ren Nutr 2009;19:29-32
64. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007;27:30-5
65. Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008;23:1892-901
66. Adijiang A, Higuchi Y, Nishijima F, et al. Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats. Biochem Biophys Res Commun 2010;399:637-41
67. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010;20(Suppl 1):S2-6
68. Niwa T, Shimizu H. Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr 2012;22:102-6
69. Muteliefu G, Enomoto A, Jiang P, et al. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 2009;24:2051-8
70. Muteliefu G, Shimizu H, Enomoto A, et al. Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21 and prelamin A through oxidative stress. Am J Physiol Cell Physiol 2012;303:C126-34
71. Shimizu H, Hirose Y, Goto S, et al. Indoxyl sulfate enhances angiontesin II signaling through upregulation of epidermal growth factor receptor expression in vascular smooth muscle cells. Life Sci 2012;91:172-7
72. Lin CY, Hsu SC, Lee HS, et al. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. J Vasc Surg 2013;57:475-85
73. Tumur Z, Niwa T. Indoxyl sulfate inhibits NO production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 2009;29:551-7
74. Tumur Z, Shimizu H, Enomoto A, et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kB activation. Am J Nephrol 2010;31:435-41
75. Adelibieke Y, Shimizu H, Muteliefu G, et al. Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity. J Ren Nutr 2012;22:86-9
76. Kharait S, Haddad DJ, Springer ML. Nitric oxide counters the inhibitory effects of uremic toxin indoxyl sulfate on endothelial cells by governing ERK MAP kinase and myosin light chain activation. Biochem Biophys Res Commun 2011;409:758-63
77. Yang K, Nie L, Huang Y, et al. Amelioration of uremic toxin indoxyl sulfate-induced endothelial cell dysfunction by Klotho protein. Toxicol Lett 2012;215:77-83
78. Adelibieke Y, Shimizu H, Saito S, et al. Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of Akt phosphorylation. Circ J 2013;77:1326-36
79. Watanabe I, Tatebe J, Namba S, et al. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J 2012;77:224-30
80. Gondouin B, Cerini C, Dou L, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 2013; [Epub ahead of print]
81. Peng YS, Lin YT, Chen Y, et al. Effects of indoxyl sulfate on adherens junctions of endothelial cells and the underlying signaling mechanism. J Cell Biochem 2012;113:1034-43
82. Wu VC, Young GH, Huang PH, et al. In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis 2013; [Epub ahead of print]
83. Yamamoto S, Zuo Y, Ma J, et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrol Dial Transplant 2011;26:2491-7
84. Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010;31:1771-9
85. Yisireyili M, Shimizu H, Saito S, et al. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 2013; [Epub ahead of print]
86. Lekawanvijit S, Kompa AR, Manabe M, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012;7:e41281
87. Fujii H, Nishijima F, Goto S, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009;24:2089-95
88. Liu S, Wang BH, Kompa AR, et al. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol 2012;158:457-8
89. Ito S, Higuchi Y, Yagi Y, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013; [Epub ahead of print]
90. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-8
91. Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012;43:451-6
92. Lin CJ, Pan CF, Liu HL, et al. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis 2012;225:173-9
93. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010;25:1183-91
94. Sato B, Yoshikawa D, Ishii H, et al. Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. Int J Cardiol 2013;163:214-16
95. Sato B, Yoshikawa D, Ishii H, et al. Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. Am J Cardiol 2013;111:712-16
96. Shimazu S, Hirashiki A, Okumura T, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 2013;77:390-6
97. Hsu CC, Lu YC, Chiu CA, et al. Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis. Clin Invest Med 2013;36:E42-9
98. Nii-Kono T, Iwasaki Y, Uchida M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007;71:738-43
99. Goto S, Fujii H, Hamada Y, et al. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial 2010;14:417-23
100. Iwasaki Y, Yamato H, Nii-Kono T, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006;21:2768-74
101. Mozar A, Louvet L, Godin C, et al. Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrol Dial Transplant 2012;27:2176-81
102. Chiang CK, Tanaka T, Inagi R, et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011;91:1564-71
103. Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-77
104. Iida S, Kohno K, Yoshimura J, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10:262-7
105. Shoji T, Wada A, Inoue K, et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 2007;105:c99-107
106. Yorioka N, Kiribayashi K, Naito T, et al. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol 2008;21:213-20
107. Konishi K, Nakano S, Tsuda S, et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;81:310-15
108. Akizawa T, Asano Y, Morita S, et al. A multicenter, randomized, controlled trial of a carbonaceous oral adsorbent's effectiveness against the progression of chronic kidney disease: the CAP-KD study. Am J Kidney Dis 2009;54:459-67
109. Nakamura T, Sato E, Fujiwara N, et al. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 2011;60:260-4
110. Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007;11:189-95
111. Nakamura T, Kawagoe Y, Matsuda T, et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004;27:121-6
112. Ueda H, Shibahara N, Takagi S, et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008;30:856-60
113. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011;6:30-9
114. Shibahara H, Shibahara N. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010;23:535-40
115. Nakai K, Fujii H, Kono K, et al. Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 2011;33:218-23
116. Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif 2013;35:196-201
117. Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012;7:982-8
118. Hida M, Aiba Y, Sawamura S, et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-55
119. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003;41(S1):S142-5
120. Taki K, Takayama F, Niwa T. Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005;15:77-80
121. De Smet R, Dhondt A, Eloot S, et al. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007;22:2006-12
122. Luo FJ, Patel KP, Marquez IO, et al. Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis 2009;53:1042-9
123. Sirich TL, Luo FJ, Plummer NS, et al. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012;27:1574-9
124. Krieter DH, Hackl A, Rodriguez A, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010;25:212-18
125. Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009;24:562-70
126. Fagugli RM, De Smet R, Buoncristiani U, et al. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002;40:339-47
127. Meyer TW, Peattie JW, Miller JD, et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 2007;18:868-74
128. Yamamoto K, Eguchi K, Kaneko I, et al. In vitro study of removal of protein-bound toxins. Blood Purif 2013;35(Suppl 1):51-4
129. Watanabe H, Miyamoto Y, Honda D, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 2013;83:582-92